

E #	Year	Title
E-016-2013	2013	Use of a high-sensitivity assay to measure midkine levels in tissue from a fine needle biopsy in order to distinguish benign from malignant thyroid nodules
E-020-2013	2013	Noninvasive biomarkers of coordinate metabolic reprogramming in colorectal cancer
E-033-2013	2013	Stabilized single human CD4 domains and fusion proteins as exceptionally potent HIV-1 entry inhibitors
E-034-2013	2013	Modified griffithsin tandemers for enhanced activity and reduced viral aggregation
E-035-2013	2013	Inhibitors of the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the therapy of the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma
E-070-2013	2013	Microfabricated Polymeric Silicone Hydrogel Vessel Mimetics
E-090-2013	2013	A video-based monitoring system for continuous in-ventilated rack video acquisition and analysis to assess mouse activity and behavior.
E-093-2013	2013	Hydroxylamide-containing compounds with improved efficacy against Raltegravir-resistant strains of HIV-1 integrase.
E-094-2013	2013	Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use
E-111-2013	2013	Hydroxamate-based chelators for the complexation of Zr-89 for nuclear imaging of cancers
E-121-2013	2013	Diagnostic and prognostic utility of urinary metabolites in lung cancer patients
E-351-2013	2013	Site specific antibody drug conjugation through glycan engineering for targeted cancer therapeutics development
E-482-2013	2013	Development of photo-activable lipid-based nanoparticles ("POCKET" liposomes) as vehicles for on-demand DUAL drug delivery for cancer treatment
E-013-2012	2012	Clinically correlated biomarker response signature for the therapeutic combination of histone Deacetylase (HDAC) and mTOR inhibitors for cancer
E-019-2012	2012	Soluble engineered monomeric IgG1 Fc
E-036-2012	2012	Production of Regulatory B (Breg) cells by a Genetically Engineered Heterodimeric Interleukin-35 Cytokine:IL-35-induced Bregs as Immunotherapy for Autoimmune Diseases
E-038-2012	2012	Development of Therapeutic RNA switches to Eradicate Viral Reservoirs in HIV infected patients
E-039-2012	2012	Auto recognizing therapeutic R/DNA chimeric nanoparticles (NP) a novel concept for HIV treatment.
E-042-2012	2012	Usage of epoxy-guaiane derivatives in the treatment of insulin resistance
E-044-2012	2012	Novel GDNF isoforms and cis-antisense GDNFOS gene
E-045-2012	2012	THIO ANALOGS OF LENALIDOMIDE
E-048-2012	2012	Expression of protein-coding and noncoding genes as a prognostic classifier in early stage, lung adenocarcinoma
E-068-2012	2012	A device to simulate explosive blast for use in real time imaging of cells and tissues
E-078-2012	2012	A Chimeric Antigen Receptor Targeting the Tumor Antigen Mesothelin
E-084-2012	2012	Polarimetric accessory for colposcope
E-086-2012	2012	Methods for cell immortalization and generation of pluripotent cells.
E-132-2012	2012	Novel vaccination strategy to alter the breath and immunodominant hierarchy of immune responses
E-135-2012	2012	DNA Methylation Analysis for The Diagnosis of Adrenal Neoplasms
E-174-2012	2012	In Vitro Generation of Memory Stem Cell-like T Cells
E-201-2012	2012	Usage of epoxy-guaiane derivatives in the treatment of patients having T lymphocytopenia
E-223-2012	2012	Co-transcriptional production of chemically modified functional therapeutic RNA nanoparticles.
E-248-2012	2012	Interferon gamma restores retinal pigment epithelial (RPE) fluid absorption suppressed by small molecule cancer therapeutic drug Meki (Merck)
E-251-2012	2012	"A highly efficient protocol for generating fully-differentiated and functional RPE cells from iPS cells."
E-281-2012	2012	Cell permeable Inhibitor of the T Cell Alternative p38 Activation Pathway
E-284-2012	2012	A Method for Treating X-linked Retinoschisis by Intravitreal Injection of an AAV Retinoschisin Vector The Use of Soluble CD27 (sCD27) in Sera of Patients with Carcinoma to Determine Response to Therapy or Suitability for Immunotherapy, and Use of sCD27 as a
E-005-2011	2011	Therapeutic to Enhance Immune Response of Patients
E-015-2011	2011	A new chemical class of antiandrogen for the treatment of castrate-resistant prostate cancer

U.S. Department of Health and Human Services
National Institutes of Health
National Cancer Institute
Technology Transfer Center

E #	Year	Title
E-024-2011	2011	The development of L2, an anti-TEM8 antibody that targets pathological angiogenesis
E-026-2011	2011	Diagnosis and Treatment of Adrenocortical Tumors Using Human microRNA-483
E-054-2011	2011	The Development and Use of a Recombinant Poxvirus-Based Vaccine for the Prevention and/or Therapy of Human Cancer
E-063-2011	2011	X-Clometer: A Radiographic Marker that Displays and Transmits Upright Angle in Degrees on Portable Chest and Abdomen X-Rays
E-068-2011	2011	Human monoclonal antibodies cross-reacting to insulin-like growth factor (IGF) I and II
E-075-2011	2011	Method for diagnosing age related macular degeneration (AMD) in a patient based on the methylation state of IL17RC
E-081-2011	2011	Hydroxytropolone inhibitors of HIV-1 and XMRV ribonuclease H
E-092-2011	2011	The use of (2S,6S)-hydroxynorketamine and other hydroxylated metabolites of (R,S)-ketamine in the treatment of depression
E-096-2011	2011	P53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer
E-130-2011	2011	Human single-domain glypican-3 monoclonal antibody, HN3, which inhibits hepatocellular carcinoma growth
E-131-2011	2011	The Development of Antioxidant NSAID For Chronic Treatment of Diseases Related to Inflammation
E-144-2011	2011	Enhancing Anti-Cancer Effect of Hypoxia-Sensitive Treatments Using Pyruvate as an Acute Hypoxia Inducer
E-151-2011	2011	Inhibition of Tumor Progress and Metastasis using Myeloid-Specific Genetic Deletion of TGFbeta signaling
E-165-2011	2011	High potency recombinant human soluble receptor for advanced glycation end products (sRAGE) as a therapeutic reagent for the treatment of vascular diseases, injuries and inflammation.
E-168-2011	2011	Genotype-specific vaccination against BK polyomavirus
E-212-2011	2011	Monospecific and bispecific human monoclonal antibodies targeting nonoverlapping epitopes on soluble ligands
E-230-2011	2011	A Vascular Endothelial Growth Factor (VEGF) Antagonist Engineered By Disruption of Heparan Sulfate Binding
E-269-2011	2011	A Living Cell Fluorescence Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources
E-275-2011	2011	A Hexanucleotide Repeat Expansion in C9orf72 is the Cause of Chromosome 9p21-linked Amyotrophic Lateral Sclerosis- Frontotemporal Dementia
E-296-2011	2011	Protecting normal tissue and enhancing tumor control by combining chemotherapy with CD47 blockade.
E-003-2010	2010	Modified POTE peptide vaccine against cancer of the prostate, colon, lung, breast, ovary and pancreas
E-022-2010	2010	Programmed Death Ligand-1 (PD-L1) Immune Modulation Gene Therapy
E-034-2010	2010	A glycolipid antigen stimulating NKT cell anti-tumor immunity
E-048-2010	2010	Improved Pepper Spray for Repellency and Incapacitation of People and Animals
E-050-2010	2010	Use of withanolides to sensitize cancer cells to the cytotoxic effects of Apo2L/TRAIL
E-092-2010	2010	Use of Sterculic acid to treat choroidal neovascularization
E-099-2010	2010	The role of IL-22 and C5a in the pathogenesis of age related macular degeneration
E-101-2010	2010	Cancer-induced regulatory B cells (tBregs) are efficient suppressors of immune cellular responses
E-103-2010	2010	Bispecific antibody soluble receptor Fc fusion proteins with potent and broad HIV-1 neutralizing activity
E-113-2010	2010	Nitissinone (NTBC) For Treatment of Oculocutaneous/Ocular Albinism and For Cosmetic Tanning
E-167-2010	2010	Peptide inhibitors of interferon gamma and interleukin 10 signaling
E-170-2010	2010	Structure-based inhibitors of 6-hydroxymethyl-7, 8-dihydropterin pyrophosphokinase (HPPK) as lead compounds for novel antibiotics
E-199-2010	2010	Fluoroquinolone derivatives as inhibitors of human tyrosyl-DNA phosphodiesterase (Tdp1)
E-226-2010	2010	A Non-Invasive Method to Predict Conduction Delays of Nerve Impulses Along White Matter Pathways
E-228-2010	2010	A Novel Method to Rapidly Isolate Tumor Specific Central Memory CD8+ T Cells
E-234-2010	2010	Biomarkers for prostate cancer and methods for their detection.
E-236-2010	2010	Anti-MAGE-A3 T Cell Receptors and Related Materials and Methods of Use
E-239-2010	2010	Manipulation of human stem cell functions by natural p53 isoforms and the ability of delta133Np53 to regulate the frequency of induced pluripotent stem cells

U.S. Department of Health and Human Services
National Institutes of Health
National Cancer Institute
Technology Transfer Center

E #	Year	Title
E-293-2010	2010	Lipopeptide inhibitors of RAS oncoproteins
E-294-2010	2010	Allele specific shRNAs and siRNAs for NanogP8.
E-023-2009	2009	Genomics-based Breast Cancer Diagnostic Assay
E-024-2009	2009	Molecular prediction of survival outcome of human hepatocellular carcinoma (HCC) patients by a 'driver'-gene-signature
E-025-2009	2009	Ratio based biomarker of survival utilizing PTEN and phospho-AKT.
E-042-2009	2009	A human cytolytic T lymphocyte epitope from the human tumor-associated antigen NGEP (new gene expressed in prostate)
E-043-2009	2009	Development of a T-Cell Receptor Targeted to the Human Tyrosinase Tumor Antigen
E-058-2009	2009	Generation and application of antibodies that bind GalNAca1-3Gal RNA Nanoparticles and methods of use
E-059-2009	2009	
E-089-2009	2009	Sperm-derived SPANX-B Is A Clinically Relevant Tumor Antigen That Is Expressed In human Tumors And Readily Recognized By Human CD4+ And CD8+ T Cells
E-091-2009	2009	Human monoclonal antibody variable fragments (Fvs) to mesothelin
E-133-2009	2009	Use of Tempol for Treatment of Cancer
E-134-2009	2009	Engineering rhythmic and responsive biological pacemakers based on the enhancement of cell intracellular signaling targeting both Ca cycling and sarcolemma
E-158-2009	2009	15kD granulysin causes monocyte activation and differentiation and may prove a useful adjuvant for immunotherapy
E-159-2009	2009	Mutation of critical lysines in the LAT adapter molecule leads to enhanced T cell signaling
E-162-2009	2009	Inhibitors of FKBP52-Mediated Regulation of Androgen Receptor Function A panel of fully human monoclonal antibodies to the same epitope of an unknown cell surface antigen expressed in B-cell chronic lymphocytic leukemia (B-CLL) (JML
E-163-2009	2009	1)
E-170-2009	2009	Methods of Preparing Lymphocytes that Express Interleukin-12 and Their Use in the Treatment of Cancer
E-181-2009	2009	Development of peptide mimetic ligands of polo-like Kinase 1 polo box domain The natural product schweinfurthin A and synthetic Schweinfurthin analogs specifically inhibit NF1-null cells and may be useful as a therapy for neurofibromatosis
E-183-2009	2009	type 1
E-191-2009	2009	Akt-Ser473 Phosphorylation and Taxane-Based Chemotherapy
E-205-2009	2009	Chimeric T cell Receptors Directed Against the Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
E-232-2009	2009	Human Domain Antibodies Against Components of the Human Insulin-Like Growth Factor (IGF) System.
E-263-2009	2009	Antiangiogenic Small Molecule Signature
E-266-2009	2009	Development of a vaccine composed of CpG oligonucleotides conjugated to apoptotic tumor cells to treat cancer
E-012-2008	2008	Inhibition of wild type and nucleoside analog resistant HIV-1 reverse transcriptase mutants using alkyl-group modification of the deoxyribose ring of adenosine.
E-032-2008	2008	Shewanella sp. MR-4 capsular polysaccharide/protein conjugates as potential vaccines against Bacillus anthracis
E-033-2008	2008	Dignostic and therapeutic applications of a p53 isoform (Delta133p53) in regenerative medicine, aging and cancer
E-051-2008	2008	"Chemoarp" A Simple and Efficient Technology for delivering siRNA
E-054-2008	2008	Discovery of a selective and specific Chk2 inhibitor
E-056-2008	2008	RPE-enriched microRNA prevent epithelial cell differentiation, proliferation, and migration. And control transepithelial electrical resistance, with significant implications in disease.
E-064-2008	2008	Epoxy-Guaiane Selective Renal Cancer Inhibitors
E-077-2008	2008	Effective Mucosal Vaccination Using Gene Delivery Vectors

U.S. Department of Health and Human Services
National Institutes of Health
National Cancer Institute
Technology Transfer Center

E #	Year	Title
E-079-2008	2008	Human monoclonal antibody against mesothelin
E-124-2008	2008	Anti-HIV Activity of New Monophosphorylated Acyclovir based Compounds
E-147-2008	2008	Tumor Targeted thermally sensitive liposomes
E-169-2008	2008	Interferon gamma inhibits human retinal pigment epithelium proliferation and migration
E-182-2008	2008	Use of Suppressive Oligonucleotides to prevent/treat Silicosis and Asbestosis
E-185-2008	2008	High-mobility group N1 protein (HMGN1) is an immune enhancer
E-247-2008	2008	Lasonolide A is a potent inducer of premature chromosome condensation
E-249-2008	2008	Phantoms for Calibration of Magnetic Resonance Diffusion Measurements In Vivo Quantitative Tissue Oxygen Imaging Using Pulsed Time-Domain Electron Paramagnetic Resonance Using a Combination of Electron Spin-Echo and Single Point
E-250-2008	2008	Imaging - ESPI (Echo-based Single Point Imaging)
E-276-2008	2008	Magnetic Resonance Specimen Evaluation Using Multiple Pulsed Field Gradient Sequences
E-283-2008	2008	Method for detection of cancer based on spatial genome organization
E-295-2008	2008	Novel inhibitor of NFkB (Nuclear factor kappa B pathway inhibitor composition and use of same)
E-296-2008	2008	Use of Suppressive Oligonucleotides to reduce host susceptibility to cancer
E-317-2008	2008	Identification of Renal Carcinoma Biomarkers
E-322-2008	2008	Method of AIDS vaccine
E-336-2008	2008	The CA125/MUC16 binding domain and related peptides
E-339-2008	2008	A multi-component Vaccine for Malaria Providing Long Lasting Immune Response Against Both Asexual and Sexual Stages of Plasmodia
E-014-2007	2007	Peptide and peptidomimetic inhibitors of Smoothed protein as anti-neoplastic agents.
E-056-2007	2007	Apparatus for Microarray DNA Binding Sensors Using Carbon Nanotube Transistors
E-059-2007	2007	Identification and Characterization of a Mouse T Cell Receptor Recognizing HLA-A*0201 Restricted Human Melanoma Antigen gp100154-162*
E-083-2007	2007	Use of SLCO1B3 Genotyping to Predict a Survival Prognosis of Prostate Cancer Utilization of Selenocysteine as an Engineered Interface Between Antibodies and Small Synthetic Molecules for the Generation of Uniquely Defined Hybrid Molecules
E-146-2007	2007	that by Combining Properties of Antibodies and Small Synthetic Molecules Have Broad Applicability in Medicine
E-150-2007	2007	Regulation of Melanocyte and Melanoma Cell Growth and Differentiation by SOX9
E-164-2007	2007	Compounds binding to the N-terminal domains of STAT proteins as therapeutic
E-166-2007	2007	Discovery of and Use of Fragments of DOC1 as Antiangiogenic and Antitumor Therapy
E-200-2007	2007	Folate Ester Derivatives of O6-Benzyl-2'-Deoxyguanosine and O6-[4-(hydroxymethyl) benzyl]guanine.
E-206-2007	2007	New Cellular Model for Studying Defects in Cholesterol Synthesis (Filed in UK as Substrate Reduction Therapy)
E-250-2007	2007	Discovery of a New Class of Inhibitors That Promote the Internalization of Specific Surface Receptors
E-298-2007	2007	Synergy Between Toll-like Receptors Using MyD88-dependent and MyD88-Independent Signaling Pathways Focused ion beam-secondary ion mass spectrometry (FIB-SIMS) as a clinical diagnostic tool for determining protein composition in mammalian cells using peptide
E-313-2007	2007	fusion tags.
E-315-2007	2007	Novel natural product inhibitors of ABCG2
E-316-2007	2007	Novel inhibitors of ABCG2 from the Developmental Therapeutics Program compound collection.
E-326-2007	2007	Development of a Genomics Approach to a Differentiating Benign from Malignant Thyroid Cancer
E-332-2007	2007	Small Molecule Inhibitors of Signaling by the Hepatocyte Growth Factor Receptor, c-Met
E-027-2006	2006	IDENTIFICATION OF INACTIVATING MUTATIONS OF THE PDE11A GENE
E-046-2006	2006	Small molecules for imaging protein - protein interactions.
E-080-2006	2006	A New Series of Thalidomide Analogs That Have Potent Anti-angiogenic Properties
E-097-2006	2006	Tetracyclines and derivatives as inhibitors of human tyrosyl-DNA-phosphodiesterase (Tdp1).

U.S. Department of Health and Human Services
National Institutes of Health
National Cancer Institute
Technology Transfer Center

E #	Year	Title
E-106-2006	2006	T-cell Receptor Recognizing Renal Cell Carcinoma A water soluble small molecule inhibitor of p53 degradation: Pyrimido [4,5-b]quinoline-2,4(3H, 10H)-dione,5-[[3-(dimethylamino)propyl]amino]-3,10-dimethyl-
E-138-2006	2006	,monohydrochloride. (NCS#373989)
E-154-2006	2006	Human gamma-8 DNA is a new chromatin insulator for the persistent expression of integrated transgenes.
E-160-2006	2006	Derivatives of 2-[2'-(2-aminoethyl)-2-methyl-ethyl]-1, 2-dihydro-6-methoxy-3H-dibenz-[de,h] isoquinoline-1,3-dione as targeted antitumor agents.
E-164-2006	2006	Tomographic Reconstruction of the 3-D "average propagator" from diffusion weighted MR data using an iterative scheme
E-256-2006	2006	Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intr-tumor delivery of anti-cancer drugs.
E-263-2006	2006	METHODS OF DETERMINING THE PROGNOSIS OF AN ADENOCARCINOMA
E-271-2006	2006	DNA-based strategy to elicit therapeutic anti-tumor responses against tumors expressing oncofetal antigen-immature laminin receptor protein (OFA-iLRP)
E-286-2006	2006	UGRP1/SCGB3A2 is a novel growth factor and anti-apoptotic agent
E-298-2006	2006	Segmenting Colon Wall Via Level Set Techniques.
E-314-2006	2006	Virtual Colonoscopy Via Wavelets
E-001-2005	2005	"Carbohydrate-encapsulated gold nanoparticles as novel antimetastatic agents."
E-027-2005	2005	Chemoattractant-based toxins which deplete T regulatory cells to improve vaccine immune responses for cancer and other clinically relevant diseases
E-038-2005	2005	ULTRAHIGH-RESOLUTION FIBER-OPTIC CONFOCAL MICROSCOPY BEYOND THE DIFFRACTION LIMIT IN THE NONOMETRIC SCALE
E-128-2005	2005	Human Artificial Chromosomes with a Predetermined Sequence as a Novel System for Gene Delivery and Gene Targeting
E-180-2005	2005	Scytovirin Domain 1 (SD1), an Antiviral Peptide.
E-183-2005	2005	NEW METHODS FOR CONJUGATION OF BACTERIAL LIPOLIGOSACCHARIDES TO PROTEIN CARRIERS THROUGH OXIME AND HYDRAZONE LINKAGES
E-211-2005	2005	Inhibitors of the protein kinase Chk2 to abrogate apoptosis and sensitize cancer cells to DNA targeted therapies
E-221-2005	2005	Fast Electron Paramagnetic Resonance Imaging (EPRI) Using CW EPR Spectrometer with Sinusoidal Rapid-Scan and Digital Signal Processing: [Rapid-Scan DSP EPRI]
E-267-2005	2005	Optimization of expression of human Interleukin-12 (IL-12) for vaccine and immunotherapy
E-279-2005	2005	Polysaccharide-Derived Nitric Oxide-Releasing Carbon-Bound Diazeniumdiolates
E-309-2005	2005	Use of replicators to prevent gene silencing
E-319-2005	2005	Triapine-induced tumor cell radiosensitization
E-336-2005	2005	Human IGF-I specific IGF-I and IGF-II cross-reactive human monoclonal antibodies.
E-092-2004	2004	Anti-Marinobufagenin Antibody (clone 3EG) and Uses to Treat Hypertension, Pre-eclampsia and Eclampsia
E-094-2004	2004	A Rapid, Sensitive Flow Cytometric Assay of Whole Blood for Pharmacodynamic Monitoring of Histone Deacetylase Inhibitors
E-116-2004	2004	Coacervate Microparticles Useful for the Sustained Release Administration of Therapeutic Agents.
E-124-2004	2004	A Diagnostic Tool for Diagnosing Benign Versus Malignant Thyroid Lesions
E-181-2004	2004	PREPARATION AND USE OF ORGANIC COMPOUNDS
E-233-2004	2004	Live Microbial Microbicides
E-244-2004	2004	The Ube2G2 Binding Domain in the ubiquitin Ligase GP78 and Methods of Use Thereof
E-263-2004	2004	POT1 (Protection of Telomeres) Alternative Splicing Variants in Hereditary Nonpolyposis Colorectal Carcinoma (HNPCC)
E-287-2004	2004	Mabs to IRTA2 for use in diagnosis and therapy of IRTA-expressing cancers
E-317-2004	2004	Synthetic Metal Ion Chelating Amino Acid Suitable for Use in Solid Phase Peptide Synthesis
E-330-2004	2004	Synthesis of EPC (4-Nitrophenyl-6- (O-phosphocholine) hydroxyhexanoate): Novel Reactants and Synthesis Process A variant of humanized COL-1 antibody rendered less immunogenic by replacing, with their human counterparts, most of the murine framework residues that were
E-339-2004	2004	presumed crucial for antigen binding
E-340-2004	2004	A Method to Enable Normal Lymphocytes to Survive and Function In Vivo in the Absence of Exogenous Cytokine Administration

U.S. Department of Health and Human Services
National Institutes of Health
National Cancer Institute
Technology Transfer Center

E #	Year	Title
E-061-2003	2003	Long Term Retrievable Venous Filter
E-063-2003	2003	Adoptive T Cell Therapy Using Rapamycin-resistant, CD28 Co-stimulated Th1/Th2 and Tc1/Tc2 Cells
E-079-2003	2003	DT-MRI AND CONSIDERATIONS OF WATER DIFFUSION
E-137-2003	2003	A Peptide Vaccine to Prevent the Development of Resistance of HIV and Hepatitis B to HIV Medications Discovery of a Novel method for the Preparation of Carbohydrate-Encapsulated Quantum Dots for Cell-Specific Biological Imaging
E-325-2003	2003	
E-060-2002	2002	Novel DNA Binding Polyamide Drug Conjugates p-Toluenesulfonylhydrazide Derivatization for Separation and Measurement of Endogenous Estrogen Metabolites by High-Performance Liquid Chromatography-
E-103-2002	2002	Electrospray-Mass Spectrometry
E-243-2002	2002	Recombinant Vaccinia Viruses Expressing IL-15 and Methods of Using the Same
E-280-2002	2002	TISSUE MICRO-OSMOMETER
E-321-2002	2002	BASE and BESE, Genes and Proteins Expressd in Breast Cancer (New genes and proteins expressed in breast cancer)
E-081-2001	2001	Zebularine, a stable and orally active inhibitor of cytosine DNA methyltransferase capable of reactivating dormant tumor suppressor genes.
E-264-2001	2001	A mouse model for von Hippel-Lindau disease: conditional VHL knockout mouse using Cre-lox site-specific recombination technology
E-317-2001	2001	Compounds to Treat HIV Infection and AIDS
E-009-2000	2000	Isolation of a high affinity Fv that binds to a mutant form of the EGF receptor.
E-014-2000	2000	Secreted Frizzled Related Protein, sFRP, Fragments and Methods of Use Thereof
E-060-2000	2000	Information concerning the inhibitory effect of sFRP-1 on osteoclast differentiation
E-134-2000	2000	Utilization of non-viral sequences to mediate (-)strand DNA transfer and efficient gene reconstitution
E-157-2000	2000	Immunogenicity Using a Combination of DNA and Vaccinia Virus Vector Vaccines
E-186-2000	2000	Improved Needle/probe for the Application of Radio-frequency Energy to Soft Tissue Tumors
E-259-2000	2000	PROTEIN KINASE A AND CARNEY COMPLEX
E-262-2000	2000	SH2 Domain Binding Inhibitors Expression vectors able to elicit improved immune response and methods of using same
E-308-2000	2000	
E-323-2000	2000	Activated Dual Specificity Lymphocytes and Their Method of Use
E-019-1999	1999	Acylated oligopeptide derivatives having cell signal inhibiting activity.
E-020-1999	1999	A Method of Immunizing Humans Against Salmonella Typhi Using a Vi-rEPA Conjugate Vaccine Non-phosphorylated, Hydrophobic Linker-Containing Cyclic Peptide Inhibitors of SH2 Domain Binding to Target Protein, Conjugates Thereof, Compositions and Methods of Use.
E-081-1999	1999	
E-105-1999	1999	Phenylalanine Derivatives Inhibition of MXR Transport by Acridine Derivatives
E-258-1999	1999	Resonant Structure for Spatial and Spectral-Spatial Imaging of Free Radical Spin Probes Using Radiofrequency Time Domain Electron Paramagnetic Resonance
E-166-1997	1997	Spectroscopy
E-167-1997	1997	The Use of a Nitroxide and a Prodrug Thereof in the Prophylatic and Therapeutic Treatment of Cancer
E-185-1997	1997	Isolation, cloning, detection, and biologic function of wild type, attenuated, and dominant negative variant cDNAs of Stat6: Stat6a, Stat6b, and Stat6c
E-193-1997	1997	Complex of Biotinylated Viral Vector and Ligand for Targeted Gene

U.S. Department of Health and Human Services
National Institutes of Health
National Cancer Institute
Technology Transfer Center

E #	Year	Title
E-244-1997	1997	(Antitumor) Macrocyclic Lactones, Compositions and Methods of Use
E-268-1997	1997	Induction of Mucosal and Systemic CTL and Protective Immunity Against Mucosal Pathogen Challenge by Intrarectal Immunization with Peptide Vaccines
E-124-1996	1996	FRAG1, a gene which potently activates fibroblast growth factor receptor 2.
E-137-1996	1996	Double-Stranded RNA Dependent Protein Kinase Derived Peptides to Promote Proliferation of Cells and Tissues in a Controlled Manner.
E-117-1995	1995	Antiviral Proteins and Peptides
E-044-1991	1991	Non-Mitogenic Competitive HGF Antagonist
E-152-1991	1991	Multideterminant Peptide Antigens that Stimulate Helper T Lymphocyte Response to HIV in a Range of Human Subjects
E-198-1991	1991	Heparin And Sulfatide-Binding Peptides From The Type I Repeats of Human Thrombospondin
E-071-1990	1990	Nitroxides as Protectors Against Oxidative Stress
E-133-1990	1990	Gossypol acetic acid for treatment of Metastatic Adrenal Cancer
E-177-1990	1990	ACTIVITY-DEPENDENT NEUROTROPHIC FACTOR
E-001-1989	1989	Human Derived Monocyte Attracting Purified Peptide Products for Treating Human Infection and Neoplasms in a Human Body.
E-214-1987	1987	Novel Interleukin 2 Receptor and Applications Thereof
E-454-1986	1986	Virus Isolation and Viral Products of Human B-Lymphotropic Virus (HBLV)
E-660-1984	1984	Production of Human T-Cell Leukemias (Lymphotropic) Retrovirus (HTLV-I Envelope Protein Fragments in...